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Previewsproteins at the Glt2 ICR, although in this
case their analyses did not allow them to
determine whether these interactions
occur on the maternal or on the paternal
chromosome. The Dlk1/Glt2 locus is
somewhat analogous to the Igf2/H19
locus in gene organization and regulation
(Wan and Bartolomei, 2008). An ICR adja-
cent to the Gtl2 promoter regulates Gtl2
and the far upstream Dlk1. The results of
Kernohan et al. support the idea that inter-
actions of cohesin, MeCP2, and ATRX
proteins are of general importance and
not restricted to H19/Igf2. However,
several differences between the two loci
suggest that the nature of these interac-
tions may not be straightforward. At
Dlk1/Glt2, the proteins each bind to
distinct parts of the ICR and not to a single
region, like they do at the H19 locus.
Furthermore, MeCP2 binding to the ICR
is ATRX dependent at Glt2, but ATRX
independent at H19.
By several criteria, Igf2, H19, Dlk1, and
Glt2 are part of a network of at least 10 im-
printed genes (Varrault et al., 2006). These
genes all share developmental and tissue-
specific patterns of expression and re-
spond similarly to mutations at the Zac1
locus. Curiously this network shows
almost no overlap with imprinted genes
involved in interchromosomal interactions170 Developmental Cell 18, February 16, 201with the H19 ICR. Kernohan et al. provide
good evidence that ATRX is required for
the downregulation of expression of
each of these genes in late embryonic or
in postnatal development. The key ques-
tion remains whether this downregulation
is important in the ATR-X syndrome.
Evolutionary theory and the analysis of
many knockout mouse strains both
support the idea that the primary effect
of imprinting is on fetal and early neonatal
growth. However, some experiments
have suggested a role for imprinted genes
in brain development and function (Wilkin-
son et al., 2007). Chimeric animals gener-
ated by mixtures of wild-type and gyno-
genetic (maternal chromosomes only)
cells, or by mixtures of wild-type and an-
drogenetic (paternal chromosomes only)
cells, show divergent phenotypes with gy-
nogenetic and androgenetic cells each
contributing to distinct brain structures
(Keverne et al., 1996). These experiments
are hard to interpret on a molecular level.
Gynogenetic cells not only lack any
paternal-specific transcripts, but also
have 2-fold overexpression of all ma-
ternal-specific RNAs. Nonetheless the
results are intriguing. Mammalian cells
go to great effort to carefully regulate the
doses of imprinted genes. Whether mis-
expression of H19 or of any of the im-0 ª2010 Elsevier Inc.printed genes plays a clinically important
role in brain development and function is
an important and difficult question that
remains to be addressed.
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Transmembrane growth factor and integrin matrix receptors form multiprotein signaling complexes with
FAK, a cytoplasmic cell motility-associated kinase. In a recent issue of Molecular Cell, Long et al. now
show that a PAK-phosphorylated alternate-spliced isoform of the steroid receptor coactivator-3
(SRC-3D4) bridges EGFR and FAK, enhancing breast carcinoma cell migration and metastasis.Cell movement results from the coordina-
tion of actin cytoskeletal and cell adhe-
sion site formation-turnover alterations
generating shape and traction force
changes. Focal adhesion kinase (FAK) is
a cytoplasmic tyrosine kinase that coloc-
alizes with and is activated by integrinmatrix receptors at adhesion sites. For
a cell to process motility-promoting
stimuli correctly, there must be essential
proteins that function as ‘‘integrators’’ in
the coordination of signals regulating cell
shape, adhesion, and cell motility. FAK is
one such integrator linking transmem-brane integrin, growth factor, and G
protein-linked receptors to the cell motility
machinery (Mitra et al., 2005). FAK is
required for efficient epidermal growth
factor (EGF)-stimulated cell motility and
this connection is facilitated through FAK
FERM (band 4.1, ezrin, radixin, moesin
Figure 1. Model for SRC-3D4-Mediated EGFR and FAK Interaction
EGF-stimulated EGFR activation results in PAK activation, potentially via Nck adaptor protein binding to
EGFR. PAK-mediated SRC-3D4 phosphorylation at T56 and S659/S676 promotes its binding to EGFR and
the FERM domain of FAK, respectively. FAK activation and autophosphorylation at Y397 occurs after
integrin clustering (via paxillin and talin binding) or via SRC-3D4-mediated changes in FAK FERM confor-
mation. SRC-3D4 enhances FAK phosphorylation at Y925, potentially via enhanced activation of c-Src
within a FAK-c-Src integrin signaling complex. FAK Y925 phosphorylation promotes Grb2 adaptor protein
binding to FAK. (Inset) SRC-3 consists of a nuclear localization sequence (NLS) region, a serine-threonine
rich domain (S/T), a nuclear receptor interacting domain (RID), a CBP interacting domain (CID), and
a histone acetyltransferase (HAT) domain. SRC-3D4 lacks the NLS region and is cytoplasmically distrib-
uted. SRC-3D4 S659/S676 phosphorylation sites lie within the RID that binds FAK FERM.
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Previewshomology) domain association with acti-
vated EGF receptor (EGFR) signaling
complexes. Simplistically, FAK activation
triggers its autophosphorylation at tyro-
sine 397 (Y397), allowing c-Src tyrosine
kinase to bind to phosphorylated Y397
FAK and generating a FAK-c-Src sig-
naling complex. Although FAK FERM
may bind directly to other growth factor
receptors (Chen and Chen, 2006) and
various studies have connected EGFR-
FAK-c-Src signaling to tumor cell inva-
siveness and metastasis (Mitra and
Schlaepfer, 2006), FAK association with
EGFR is indirect and the molecular details
of this linkage have remained elusive.
Reporting in a recent issue ofMolecular
Cell, Long et al. (2010) have now identified
the alternate-spliced isoform of steroid
receptor coactivator-3 (SRC-3)—termed
SRC-3D4 (deletion of exon 4)—as anEGFR-FAK bridging protein. Full-length
SRC-3/AIB1 (amplified in breast can-
cer-1) is a member of the p160 family of
cotranscriptional regulators of hormone-
bound nuclear receptors (Lahusen et al.,
2009). Interestingly, inhibition of SRC-3
expression altered FAK localization and
prevented ovarian carcinoma cell motility
(Yoshida et al., 2005), and SRC-3 overex-
pression enhanced FAK activation and
prostate carcinoma invasion (Yan et al.,
2008). However, no direct connection
between SRC-3 and FAKwas established
and these effects may have been related
to transcriptional modulation of cell-
matrix interactions. SRC-3D4 is produced
from a second translational start site,
does not contain a nuclear localization
sequence, and is cytoplasmically distrib-
uted; SRC-3D4 expression is also
elevated in breast cancer (Reiter et al.,Developmental Cell 18,2004). Long et al. (2010) now show that
SRC-3D4 colocalizes with FAK at the
leading edge of motile MDA-MB231
breast carcinoma cells and that SRC-
3D4 forms a complex with FAK. Direct
binding was confirmed between the FAK
FERM domain and the central receptor in-
teracting domain (RID) of SRC-3D4.
Notably, SRC-3D4 was required for effi-
cient EGF-stimulated MDA-MB231 cell
motility. The knockdown of SRC-3D4 de-
creased EGFR-FAK association, whereas
EGF stimulation enhanced SRC-3D4 asso-
ciation with FAK. These results support a
role for SRC-3D4 in linking EGFR to FAK.
This bridge model was further support
by the fact that SRC-3D4 also bound to
EGFR via the amino-terminal domain of
SRC-3D4. As EGF stimulation enhanced
the formation of a complex between
EGFR, SRC-3D4, FAK, and the serine-
threonine kinase PAK1, Long et al.
(2010) explored the hypothesis that
PAK1 phosphorylation of SRC-3D4 may
strengthen the EGFR, SRC-3D4, and
FAK linkage. PAK1 is a cytoskeletal-
associated kinase activated by small
GTP binding proteins and functions
downstream of FAK signaling (Bokoch,
2003). However, PAK1 can also be proxi-
mally recruited to activated EGFR
signaling complexes and possibly func-
tion upstream of FAK. Although the
temporal nature of PAK1 activation was
not addressed, Long et al. (2010) found
that PAK1 directly phosphorylated three
sites on SRC-3D4: threonine 56 (T56)
within the SRC-3D4 amino-terminal (NT)
domain, and serines 659 (S659) and 676
(S676) within the SRC-3D4 RID. These
are the domains that mediate SRC-3D4
binding to EGFR and FAK, respectively.
Accordingly, mutation of T56 disrupted
EGFR association with the SRC-3D4 NT
domain and mutation of S659/S676 dis-
rupted binding of the SRC-3D4 RID to
FAK. Combined triple T56/S659/S676
mutations prevented SRC-3D4 complex
formation with both EFGR and FAK and
also blocked SRC-3D4 effects on EGF-
stimulated HeLa cell migration. Because
low-level SRC-3D4 binding to FAK or
EGFR can also occur independently of
PAK1 phosphorylation, future studies will
likely need to focus on the molecular
details of these interactions.
Nevertheless, the findings made by
Long et al. (2010) provide support for an
intriguing bridging model (Figure 1)February 16, 2010 ª2010 Elsevier Inc. 171
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Previewswherein EGF-stimulated PAK activation
facilitates SRC-3D4 phosphorylation at
T56, resulting in EGFR binding. PAK-
mediated phosphorylation of SRC-3D4
at S659 and S676 promotes its binding
to the FERM domain of FAK. Interestingly,
EGF or modulation of SRC-3D4 expres-
sion did not affect FAK phosphorylation
at Y397, but SRC-3D4 knockdown was
associated with decreased FAK Y925
phosphorylation, c-Src activation, and
signaling to the ERK/mitogen-activated
protein (MAP) kinase. Phosphorylation of
FAK Y925 is mediated by c-Src and
promotes the binding of the Grb2 adaptor
protein to FAK, leading to ERK/MAP
kinase activation (Mitra and Schlaepfer,
2006). Although not directly tested, these
results imply that the SRC-3D4 linkage
enhances EGF-stimulated FAK activation
via binding to the FAK FERM domain,
leading to conformational FAK activation
and the enhanced formation of a FAK-
Src signaling complex (determined by
changes in FAK Y925 phosphorylation).
Although FAK Y925 is not essential for
normal fibroblast motility, this site is
required in promoting an angiogenic
switch in tumors (Mitra and Schlaepfer,
2006; Tomar et al., 2009). Interestingly,
when Long et al. (2010) injected MDA-
MB231 cells overexpressing SRC-3D4
(which show enhanced motility-invasion
in vitro associated with elevated FAK
Y925 phosphorylation) into mouse breast172 Developmental Cell 18, February 16, 201fat pads, these cells exhibit enhanced
lymph node and lung metastasis without
alterations in primary tumor growth.
Because increased levels of SRC-3D4
cells were found circulating in the blood,
Long et al. proposed that this may reflect
increased motility or extravasation of
tumor cells from primary tumor sites.
Overall, this study provides intriguing
results supporting a new signaling con-
nection for a cytoplasmically distributed,
alternate-spliced isoform of SRC-3.
Although this study provides valuable
steps forward in resolving some of the
mysteries surrounding the linkage
between EGFR and FAK, several ques-
tions remain. What are the SRC-3D4
binding sites on EGFR or FAK FERM,
and how does phosphorylation of SRC-
3D4 influence binding? Does SRC-3D4
link FAK to other receptors such as the
platelet-derived growth factor receptor
known to promote PAK activation and
cell motility? Because SRC-3D4 expres-
sion is generally low in noncancerous
cell types, do different mechanisms
promote FAK association with EGFR in
normal versus cancer cells? What is the
connection between tumor-associated
SRC-3D4 expression, FAK Y925 phos-
phorylation, and the invasive cell pheno-
type? Clearly, the identification of
SRC-3D4 as a bridging protein raises
many exciting new questions whose
answers are needed for understanding0 ª2010 Elsevier Inc.the molecular mechanisms initiating and
controlling cell movement.ACKNOWLEDGMENTS
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Alternative polyadenylation generates mRNAs with 30 untranscribed regions of different lengths, often
affecting transcript stability. Hornyik et al., in this issue ofDevelopmental Cell, and Liu et al. now demonstrate
a role for alternative polyadenylation in gene silencing and the regulation of flowering time in Arabidopsis
thaliana.Messenger RNA (mRNA) 30 end process-
ing defines the end of the transcript
through endonucleolytic cleavage of the
precursor transcript, provides aprotectivepolyadenylate tail, and enables subse-
quent termination of transcription by RNA
polymerase II. Just as alternative splicing
allows greater diversity of mRNA prod-ucts from a limited number of genes, in
animals and plants it is estimated that
>50% of genes have alternative polyade-
nylation (polyA) sites, the majority of
